A detailed history of Advisor Group Holdings, Inc. transactions in Chimerix Inc stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 2,400 shares of CMRX stock, worth $2,112. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,400
Holding current value
$2,112
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$0.77 - $1.07 $1,848 - $2,568
2,400 New
2,400 $2,000
Q3 2023

Nov 13, 2023

BUY
$0.94 - $1.23 $11,783 - $15,419
12,536 Added 66.39%
31,417 $30,000
Q2 2023

Aug 10, 2023

BUY
$1.1 - $1.54 $5,870 - $8,218
5,337 Added 39.4%
18,881 $22,000
Q1 2023

May 12, 2023

BUY
$1.19 - $2.09 $9,422 - $16,548
7,918 Added 140.74%
13,544 $17,000
Q4 2022

Feb 10, 2023

SELL
$1.67 - $2.35 $738 - $1,038
-442 Reduced 7.28%
5,626 $10,000
Q3 2022

Nov 14, 2022

SELL
$1.81 - $2.76 $1,659 - $2,530
-917 Reduced 13.13%
6,068 $11,000
Q2 2022

Aug 10, 2022

SELL
$1.34 - $5.34 $6,899 - $27,495
-5,149 Reduced 42.43%
6,985 $14,000
Q1 2022

May 04, 2022

BUY
$4.58 - $6.8 $26,994 - $40,079
5,894 Added 94.46%
12,134 $56,000
Q2 2021

Aug 02, 2021

BUY
$7.54 - $9.79 $22,514 - $29,232
2,986 Added 91.76%
6,240 $50,000
Q1 2021

May 13, 2021

SELL
$4.76 - $11.25 $35,566 - $84,060
-7,472 Reduced 69.66%
3,254 $31,000
Q4 2020

Feb 10, 2021

SELL
$2.43 - $5.42 $6,050 - $13,495
-2,490 Reduced 18.84%
10,726 $51,000
Q3 2020

Nov 12, 2020

BUY
$2.3 - $3.72 $23,496 - $38,003
10,216 Added 340.53%
13,216 $32,000
Q2 2020

Aug 14, 2020

BUY
$1.33 - $3.63 $3,524 - $9,619
2,650 Added 757.14%
3,000 $9,000
Q1 2020

May 18, 2020

BUY
$1.27 - $2.33 $444 - $815
350 New
350 $1,000

Others Institutions Holding CMRX

About CHIMERIX INC


  • Ticker CMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,622,896
  • Market Cap $77.1M
  • Description
  • Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...
More about CMRX
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.